We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Device Products
    • Books
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Subscription Newsletters
    • Free Newsletters
    • Webinar Training Pass
    • eCFR and Guidances
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » MULTI-SITE TRIALS AND NEW TECHNOLOGY NEED BETTER REGULATION, SAYS FDA

MULTI-SITE TRIALS AND NEW TECHNOLOGY NEED BETTER REGULATION, SAYS FDA

May 30, 2006

The FDA intends to improve supervision of multi-site clinical trials by working on a guidance on the use of coordinators who are not principal investigators (PI), an FDA official has announced.

Scott Gottlieb, deputy commissioner for medical and scientific affairs at the FDA, questioned whether it is "possible, reasonable or appropriate" for a single PI to oversee clinical trials involving 30 to 40 or more sites. He also noted that the FDA is grappling with the question of how to ensure that there is adequate and appropriate supervision in such trials.

In cases where somebody other than the PI performs the primary supervisory role, the FDA wants to develop a mechanism to make that person accountable to the agency, he said May 18 at the 2006 Clinical Research Educational Conference. "We will be asking these questions, and also developing guidance on what we view as adequate supervision by the principal investigator to help address this latter question," he said.

Gottlieb also spoke to the use of technology in clinical trials and the need for the FDA to bring its regulations up to date on this subject. Among other things, he said the agency might do more real-time inspections of clinical trials sites rather than post-hoc audits, while taking advantage of inspections the industry is already doing. The agency will also provide more common standards and regulatory requirements for electronic data handling, as well as clinical research data and data exchange standards to make collaboration easier, he said.

KEYWORDS FDAnews Drug Daily Bulletin

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 21Apr

    CDER’s Most Significant Guidance Priorities for 2021: Biosimilars/Biologics, Generics/Exclusivity, Real-World Evidence, Drug Development and Digital Health

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Biological Risk Evaluation and Management for Medical Devices

  • GMP Inspection Preparation Checklist: A Tool for Internal Auditing

Featured Stories

  • FDA logo blue

    Former Indivor Executive Seeks FDA Hearing to Avoid Debarment

  • FDA clears text

    FDA Clears Activ Surgical’s Imaging Module for ActivEdge Platform

  • Bristol Myers Squibb logo

    UK’s NICE Rejects Opdivo and Yervoy Combo for Lung Cancer

  • ClearanceStamp_Orange.gif

    Medtronic Earns De Novo Clearance for AI Colonoscopy System

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Fax 703.538.7676 – Toll free 888.838.5578

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing